Key Word(s): 1. Livin; 2. Caspase-3; 3. Caspase-3; 4. norcantharidin; Presenting Author: YU-HONG WANG Additional Authors: QIU-CHEN YANG, YUAN LIN, LING XUE, MIN-HU CHEN, JIE CHEN Corresponding Author: JIE CHEN Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-Sen University; Department of Pathology, The First Affiliated Hospital of Sun Yat-Sen University Objective: To evaluate the significance of
serum chromogranin A (CgA) levels in patients with gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) in terms of diagnosis and curative effects. Methods: 1. Results of CgA immunohistochemical (IHC) staining in 213 cases of GEP-NEN were collected between January 1995 and December 2012 in The First Affiliated Hospital, Sun Yat-sen University. Erlotinib supplier 3 MA 2. Ninety GEP-NET patients comprising 50 patients with active disease and 40 postoperative patients were enrolled in this study from January 2011 to December 2012. Serum CgA levels were measured and clinicopathological factors were also collected. Results: 1. The overall expression rate of CgA was 62.4% (133/213). Over expression of CgA was associated with female patients, pancreas tumors, Functionality
and distant metastasis (P < 0.05), but not correlated with Sorafenib mw prognosis (P = 0.07). 2. Serum CgA levels were significantly higher in GEP-NEN patients with active disease than in postoperative disease-free patients (P = 0.001) or healthy participants (P = 0.002). CgA values at 95 ng/ml distinguished healthy controls or disease-free patients from patients with active disease. Sensitivity and specificity rates were 54.0% and 90.1%, respectively. There was a significant difference in serum CgA levels between patients
with and without distant metastatic tumors (231 ng/ml vs. 46 ng/ml, P = 0.001); Patients (13/13, 100%) with stable disease and who showed complete remission and partial response after treatment had a more than 20% decrease in CgA levels compared with the baseline values. Patients (6/6, 100%) with progressive disease showed a more than 20% increase in CgA levels. CgA levels had not positive correlation with prognosis (P = 0.232). There was a positive correlation between the IHC expression and high serum levels of CgA (r = 0.280, P = 0.049). Conclusion: CgA can be used as a reliable biomarker not only for clinical diagnosis but also for the curative effects evaluation of GEP-NEN with high diagnostic value. Key Word(s): 1. gep; 2. CgA; 3. diagnosis; 4.